Nexalin Technology Inc. (NXL)
Company Description
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China.
It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia.
The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders.
It also engages in the development of Generation 2, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiates, chronic pain, Alzheimer's disease, and dementia.
The company was incorporated in 2021 and is headquartered in Houston, Texas.

Country | United States |
IPO Date | Sep 16, 2022 |
Industry | Medical - Devices |
Sector | Healthcare |
Employees | 6 |
CEO | Mark White |
Contact Details
Address: 1776 Yorktown Houston, Texas United States | |
Website | https://www.nexalin.com |
Stock Details
Ticker Symbol | NXL |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001527352 |
CUSIP Number | 65345B201 |
ISIN Number | US65345B2016 |
Employer ID | 27-5566468 |
SIC Code | 3845 |
Key Executives
Name | Position |
---|---|
Mark White | President, Chief Executive Officer, Chief Financial Officer & Director |
Carolyn Shelton | Executive Vice President of Clinical, Quality & Regulatory Affairs and Chief Operating Officer |
Dr. David Owens M.D. | Chief Medical Officer & Director |
John Patrick Claude | Co-Founder and Director of Engineering & Development |
Marilyn Elson | Controller |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 14, 2025 | 10-K | Annual Report |
Mar 13, 2025 | 4 | Filing |
Feb 27, 2025 | 4 | Filing |
Feb 27, 2025 | 4 | Filing |
Feb 10, 2025 | 5 | Filing |
Feb 06, 2025 | 8-K | Current Report |
Feb 05, 2025 | 4 | Filing |
Feb 04, 2025 | 4 | Filing |
Jan 30, 2025 | S-1/A | [Amend] Filing |
Jan 29, 2025 | 5 | Filing |